1. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).
- Author
-
Jelinek T, Mihalyova J, Kascak M, Duras J, Popkova T, Benkova K, Richterova P, Plonkova H, Zuchnicka J, Broskevicova L, Huvarova L, Cerna L, Growkova K, Simicek M, Havel M, Gumulec J, Navratil M, Koristek Z, Paiva B, and Hajek R
- Subjects
- Antineoplastic Agents pharmacology, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bortezomib administration & dosage, Bridged Bicyclo Compounds, Heterocyclic pharmacology, Chromosomes, Human, Pair 11 genetics, Chromosomes, Human, Pair 14 genetics, Combined Modality Therapy, Cyclophosphamide administration & dosage, Dexamethasone administration & dosage, Doxorubicin administration & dosage, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Plasma Cell complications, Leukemia, Plasma Cell genetics, Leukemia, Plasma Cell therapy, Male, Middle Aged, Neoplasm Proteins antagonists & inhibitors, Neoplasm, Residual, Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors, Recurrence, Sulfonamides pharmacology, Translocation, Genetic, Vincristine administration & dosage, Antineoplastic Agents therapeutic use, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Leukemia, Plasma Cell drug therapy, Molecular Targeted Therapy, Sulfonamides therapeutic use
- Published
- 2019
- Full Text
- View/download PDF